poisar

Stocks · News reference

'Major Novartis shareholder calls for board shake-up after drug trial setbacks' - Reuters Exclusive Interview

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

NVS
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Novartis

    Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)

    The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for Novartis's Cosentyx (secukinumab) for treating polymyalgia rheumatica (PMR) in adults. If approved, it would be the first IL-17A inhibitor licensed in Europe for PMR, offering an alternative to long-term steroid therapy. The recommendation is based on Phase III REPLENISH trial data showing Cosentyx doubled sustained remission rates and provided steroid-sparing effects compared to placebo, with a safety profile consistent with its established use in other autoimmune diseases.

    NVS
  4. Researchandmarkets.Com

    Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive Landscape

    The global autoimmune disease therapeutics market is projected to grow from USD 132.75 billion in 2025 to USD 254.60 billion by 2034, at a CAGR of 7.5%. Growth is driven by rising autoimmune disease diagnoses, increased adoption of biologics and targeted oral therapies, biosimilar expansion, and emerging cell and gene therapies. Biologics dominate with 66% market share, TNF inhibitors lead drug classes at 29%, and rheumatoid arthritis accounts for 34% of revenue. North America holds 44% regional share while Asia-Pacific is expected to grow fastest.

    ABBVJNJPFENVSRHHBY